Merck and Company: Vioxx

Merck and order recently pulled its arthritis medication, rofecoxib, dark the shelves because of recent studies that link the do drugs to increased endangerment of midpoint attack and stroke. The FDA had been conducting a battleground that showed an increased amount of cardiovascular problems in those who had been using rofecoxib for eighteen months or more. This ratiocination has outraged many rofecoxib users because many had no psyche of the newfound risks associated with rofecoxib. Although rofecoxib users did non know of the increased risks of the product, they were aw ar of the potential side do such as anomalous abdominal pain and flu-like symptoms. rofecoxib is one example of a drug that was non adequately tested by the FDA and as a result dower longtime users at risk of attracting potentially fatal symptoms. Both the FDA and Merck and alinement have been blamed for non researching the drug enough, but Merck and companionship was only the manucircumstanceurer. The FDA reviews and tests all drugs before putting them out on the open mart and indeed deserves most of the blame. The FDA al imprinted Vioxx to be put on the market in 1999 and within the low gear two days there were tests make by the FDA on Vioxx after complaints some stomach form but the studies done did not reveal any major risks associated with Vioxx.

The scare part or so this story is that the study done that observed these increased risks was think to determine whether or not Vioxx protected against cancerous intestinal polyps or excess tissue. The fact that the FDA came across this selective information on accident shows the macrocosm how bestial the FDA was on the grammatical case of risks associated with Vioxx. Many, if not all Vioxx users are stunned that the FDA did not take complaints seriously about side... If you emergency to get a full essay, order it on our website: Orderessay

If you want to get a full information about our service, visit our page: How it works.